Teva Of Israel Licenses Lilly Gemzar Generic To APP Pharmaceuticals
This article was originally published in PharmAsia News
Executive Summary
Israel's Teva Pharmaceutical Industries contracted with APP Pharmaceuticals to make a generic version of Eli Lilly's Gemzar (gemcitabine) chemotherapy drug
Israel's Teva Pharmaceutical Industries contracted with APP Pharmaceuticals to make a generic version of Eli Lilly's Gemzar (gemcitabine) chemotherapy drug. Teva gained a six-month exclusivity to market the drug by being the first to file for approval of a generic in the United States. The APP deal calls for licensing the generic to the Fresenius Kabi Pharmaceuticals unit to make and market the drug, paying royalties to Teva on resulting sales. The Lilly drug achieved $785 million in U.S. sales last year. (Click here for more) "Teva, APP Pharma To Launch Eli Lilly's Cancer Drug Copy" - Reuters (U.K.) (1/26/11) |